psychedelics
Psychedelic Experiences After Bereavement Improve Symptoms of Grief: The Influence of Emotional Breakthroughs and Challenging Experiences (Low, et al, 2025)
"Findings provide preliminary evidence that support the development of a psychedelic-assisted therapy protocol to target symptoms of grief. Psychedelic-assisted therapy might offer an alternative to current grief treatment options. "
ketamine
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis (Elmosalamy, et al, 2025)
"Based on the currently available comparative evidence, which is almost entirely observational, IV ketamine and IN esketamine show comparable acute response and remission rates, though IV ketamine may act faster."
ketamina
Ketamina en Cirugía Cardíaca: Una Revisión Sistemática y un Meta-Análisis de Efectos sobre Marcadores Inflamatorios y Resultados Clínicos (Ferreira de Lima E Souza, et al, 2025)
La medicina psicodélica ketamina, utilizada desde hace décadas en anestesia, manejo del dolor, salud mental y cuidados paliativos, ha sido administrada en pacientes cardíacos sin observarse cambios negativos en los resultados clínicos atribuibles a efectos adversos del fármaco.
ketamine
Unfolding States of Mind: A Dissociative-Psychedelic Model of Ketamine-Assisted Psychotherapy in Palliative Care (Gonçalves Campolina & Tuena de Oliveira, 2025)
Dissociative-psychedelic model offers a compassionate, pragmatic, theoretically grounded approach to relieving psychological & existential suffering in palliative care
ketamine
Ketamine and dodecyl maltoside synergy as a potential topical therapeutic approach for melanoma (skin cancer) (Idoudi, et al, 2025)
"These findings demonstrate that ketamine, particularly when combined with DDM, holds promise as a potential topical therapeutic strategy against melanoma."
ketamine
Racemic Ketamine vs Esketamine in Treatment-Resistant Depression: The Overlooked Role of Arketamine (Tan, et al, 2025)
Evidence suggests that "IV racemic ketamine is more effective than IN esketamine in TRD; convergent preclinical and clinical findings support the hypothesis that arketamine plays a key role in this superiority and that ketamine’s antidepressant mechanisms extend beyond simple NMDAR antagonism."
ketamine
The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews (Correa de Costa, et al, 2025)
"...evidence suggests that the use of serotonergic and non-serotonergic psychedelics (ketamine) for the treatment of SUD may provide advantages over traditional therapeutics, and these compounds may eventually become part of the next generation of treatments for SUD under specific circumstances."
ketamine
Spotlight: A long, strange trip: Ketamine treatment in psychiatry (Nutt, et al, 2025)
"...mystical experiences were strongly related to immediate and sustained psychiatric benefits at the group level and on an individual, session-by-session basis across the six doses, providing mechanistic support for ketamine-psychotherapy pairings."
ketamine
Spotlight: Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical Practice (Serretti, 2025)
"Depression is increasingly conceptualized as a disorder of impaired synaptic plasticity and excitation-inhibition imbalance within corticolimbic circuits. Ketamine, brexanolone, zuranolone, offer complementary approaches to restore circuit function."
ketamine
Spotlight: Personality profiles and trauma history in ketamine therapy for mood and anxiety disorders: A latent profile analysis of short-term outcomes (Gregoire, et al, 2025)
"Personality traits relate to baseline mental health severity but not short-term response to ketamine. Trauma history may predict greater benefit from treatment."
ketamine
Spotlight: Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction (Palhas, et al, 2025)
"Serotonergic psychedelics & ketamine appear to share common cellular mechanisms. They both recruit glutamatergic neurons to stimulate BDNF-trKB signaling, promoting synaptogenesis via the mTOR pathway. These changes may explain their efficacy in depression, anxiety, PTSD, & addiction."
salience network
Spotlight: Modulation of functional network co-activation pattern dynamics following ketamine treatment in major depression (Taraku, et al, 2025)
"findings suggest ketamine modulates brain network dynamics which may normalize dynamic patterns seen in TRD at baseline toward patterns seen in controls. Changes in Salience Network state dynamics may correspond to improvements in ruminative symptoms following ketamine therapy."
ketamine
Spotlight: Intermittent ketamine and neuromodulation treatment evoke synergistic antidepressant-relevant action (Brown, et al, 2025)
"The rapid response that can be observed following ketamine treatment has reconceptualized how pharmacotherapy can treat depression. One subanesthetic infusion can alleviate symptoms within hours; however, sustained relief also requires multiple doses. "
ketamine
Spotlight: Efficacy and safety of ketamine maintenance therapy in treatment-resistant depression: A systematic review of treatment protocols and clinical outcomes (Al-Garni, et al, 2025)
"Concurrent psychotherapy improved treatment maintenance. Adverse events were generally mild to moderate... Ketamine maintenance therapy shows promise as a treatment option for TRD, with regular dosing schedules and early intervention associated with optimal outcomes."
ketamine
Spotlight: Ketamine Assisted Therapy Outcomes for First-Responders with Comorbid Mental Health Diagnoses (Tsang, et al, 2025)
"KAT may provide meaningful benefits beyond symptom reduction."
ketamine
Spotlight: Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis (Silberbauer, et al, 2025)
Treatment was well-tolerated, with no serious adverse events reported...in a total of 592 patients, meta-analysis of randomized controlled trials on oral ketamine treatment demonstrated its antidepressant efficacy with a Number Needed to Treat = 4.89 for response and a NNT = 9.16 for remission.
opiod system
Spotlight: Antidepressants and the endogenous opioid system (Fricker, et al, 2025)
"A growing body of evidence links the opioid system w/ major depressive disorder... two different widely used antidepressants, tianeptine & ketamine, both interact with MOR; tianeptine as a full agonist, ketamine as a positive allosteric modulator. Both produce antidepressant effects within days."
ketamine
Spotlight: Synaptic priming: A framework for pharmacotherapy in depression (Brown, et al, 2025)
"we describe how the indirect relationship between ketamine's pharmacokinetics and sustained antidepressant pharmacodynamics reveals a dosing model (primer pharmacology) that can be harnessed to fine-tune therapeutic outcomes."
